BioCardia, Inc. (NASDAQ:BCDA) Short Interest Update

BioCardia, Inc. (NASDAQ:BCDA) was the recipient of a large increase in short interest in November. As of November 15th, there was short interest totalling 109,500 shares, an increase of 26.9% from the October 31st total of 86,300 shares. Based on an average trading volume of 822,600 shares, the short-interest ratio is currently 0.1 days. Currently, 3.1% of the company’s shares are sold short.

BioCardia Price Performance

Shares of NASDAQ BCDA traded down $0.02 during midday trading on Monday, reaching $2.26. The company’s stock had a trading volume of 47,220 shares, compared to its average volume of 286,014. The firm has a 50 day moving average price of $2.47 and a 200-day moving average price of $3.04. BioCardia has a 12-month low of $1.84 and a 12-month high of $10.79. The stock has a market capitalization of $10.36 million, a P/E ratio of -0.54 and a beta of 1.28.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reiterated a “buy” rating and issued a $25.00 target price on shares of BioCardia in a report on Thursday, November 14th.

BioCardia Company Profile

BioCardia, Inc, a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia.